84-1081-89　Caspase 6 (Mch 2) 100ul　C2087-27S

特徴

• Apoptosis or programmed cell death is essential for normal tissue development and abnormal growth such as cancer, neurodegeneration, autoimmune diseases, and angiogenesis, etc.
• Apoptosis is driven by caspases (cysteine proteases that cleave after an aspartic acid residue).
• After the initial discovery of the first mammalian caspase 1 or ICE (interleukin 1 beta converting enzyme), a growing family of caspases 1-14 have been cloned and characterized.
• Caspases are synthesized as inactive zymogen or proenzyme forms (30-55kD), which upon apoptotic stimulation are proteolytically processed (self or by other proteins) in a sequential manner into their active heterotetrameric forms.
• The processed form consists of large subunit (17-20kD) and a small (10-12kD) subunits, which may associate to form an active enzyme.
• Functionally active caspases initiate a proteolytic cascade, capable of cleaving and activating numerous cellular targets including PARP, G4-GDI, DFF, MEKK, etc.
• On a functional basis, two categories of caspases have been defined: the initiator caspases (caspases-8, -9, and –10) are activated in the earlier phases of apoptosis, whereas the executioner caspases (caspases-3, -6, and –7) are activated by initiator caspases and are responsible for dismantling cellular components.
• Caspase-6, (also known as ICE-6, MCH-2, CASP-6) (Zymogen 35-40kD) is mapped at human chromosome 4q25q25 and executes the final apoptotic phase.
• The processed form of human is a heterotetramer consisting of two large ~18kD and two small ~11kD subunits.
• Alternative splicing of human CASP-6 results in two isoforms: alpha (293aa) and beta (204aa) but beta isoform does not have protease activity.
• Mouse (276aa) and rat (277aa) and human CASP-6 proenzymes are activated by CASP-3, -8 or –10.
• Unlike CASP-3 and MCH-3, Hs CASP-6 (MCH-3) can cleave lamin-A and –C in their signature apoptotic fragments.
• CASP-6 mediates the shrinkage and fragmentation of nuclei.
• It is highly expressed in lung, liver, kidney, testis and heart; lower levels in spleen, skeletal muscle and brain.
• Applications:Suitable for use in Western Blot and ELISA.
• Other applications not tested.
• Recommended Dilution:Western Blotting (1-10ug/ml for affinity pure antibody using ECL technique).
• Will recognize 34kD Procaspase-6 and alternatively spliced 22kD isoform-beta
• ELISA: Control peptide can be used to coat ELISA plates at 1ug/ml and detected with antibodies ( 0.5-1ug/ml for affinity pure)
• Optimal dilution determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C.
• Stable for 12 months at -20°C.
• Reconstitute with sterile ddH2O or PBS.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Reconstituted product is stable for 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.